The metoclopramide black box warning for tardive dyskinesia: Effect on clinical practice, adverse event reporting, and prescription drug lawsuits

Eli D. Ehrenpreis, Parakkal Deepak, Humberto Sifuentes, Radha Devi, Hongyan Du, Jerrold B. Leikin

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

OBJECTIVES:We examined the effects of the black box warning about the risk of tardive dyskinesia (TD) with chronic use of metoclopramide on management of gastroparesis within a single clinical practice, and on reporting of adverse events.METHODS:Medical records of gastroparesis patients were evaluated for physician management choices. The FDA Adverse Event Reporting System (FAERS) was analyzed for event reports, and for lawyer-initiated reports, with metoclopramide from 2004 to 2010. Google Scholar was searched for court opinions against metoclopramide manufacturers.RESULTS:Before the black box warning, 69.8% of patients received metoclopramide for gastroparesis, compared with 23.7% after the warning. Gastroenterologists prescribed domperidone more often after than before the warning. Metoclopramide prescriptions decreased after 2008. Adverse event reporting increased after the warning. Only 3.6% of all FAERS reports but 70% of TD reports were filed by lawyers, suggesting a distortion in signal. Forty-seven legal opinions were identified, 33 from 2009-2010. CONCLUSIONS:The black box warning for metoclopramide has decreased its usage and increased its rate of adverse event reporting. Lawyer-initiated reports of TD hinder pharmacovigilance.

Original languageEnglish (US)
Pages (from-to)866-872
Number of pages7
JournalAmerican Journal of Gastroenterology
Volume108
Issue number6
DOIs
StatePublished - Jun 1 2013

Fingerprint

Drug Labeling
Metoclopramide
Prescription Drugs
Gastroparesis
Lawyers
Domperidone
Pharmacovigilance
Medical Records
Prescriptions
Tardive Dyskinesia
Physicians

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

The metoclopramide black box warning for tardive dyskinesia : Effect on clinical practice, adverse event reporting, and prescription drug lawsuits. / Ehrenpreis, Eli D.; Deepak, Parakkal; Sifuentes, Humberto; Devi, Radha; Du, Hongyan; Leikin, Jerrold B.

In: American Journal of Gastroenterology, Vol. 108, No. 6, 01.06.2013, p. 866-872.

Research output: Contribution to journalArticle

@article{a37bbc4af6864f9e9982c70e7e7b0770,
title = "The metoclopramide black box warning for tardive dyskinesia: Effect on clinical practice, adverse event reporting, and prescription drug lawsuits",
abstract = "OBJECTIVES:We examined the effects of the black box warning about the risk of tardive dyskinesia (TD) with chronic use of metoclopramide on management of gastroparesis within a single clinical practice, and on reporting of adverse events.METHODS:Medical records of gastroparesis patients were evaluated for physician management choices. The FDA Adverse Event Reporting System (FAERS) was analyzed for event reports, and for lawyer-initiated reports, with metoclopramide from 2004 to 2010. Google Scholar was searched for court opinions against metoclopramide manufacturers.RESULTS:Before the black box warning, 69.8{\%} of patients received metoclopramide for gastroparesis, compared with 23.7{\%} after the warning. Gastroenterologists prescribed domperidone more often after than before the warning. Metoclopramide prescriptions decreased after 2008. Adverse event reporting increased after the warning. Only 3.6{\%} of all FAERS reports but 70{\%} of TD reports were filed by lawyers, suggesting a distortion in signal. Forty-seven legal opinions were identified, 33 from 2009-2010. CONCLUSIONS:The black box warning for metoclopramide has decreased its usage and increased its rate of adverse event reporting. Lawyer-initiated reports of TD hinder pharmacovigilance.",
author = "Ehrenpreis, {Eli D.} and Parakkal Deepak and Humberto Sifuentes and Radha Devi and Hongyan Du and Leikin, {Jerrold B.}",
year = "2013",
month = "6",
day = "1",
doi = "10.1038/ajg.2012.300",
language = "English (US)",
volume = "108",
pages = "866--872",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - The metoclopramide black box warning for tardive dyskinesia

T2 - Effect on clinical practice, adverse event reporting, and prescription drug lawsuits

AU - Ehrenpreis, Eli D.

AU - Deepak, Parakkal

AU - Sifuentes, Humberto

AU - Devi, Radha

AU - Du, Hongyan

AU - Leikin, Jerrold B.

PY - 2013/6/1

Y1 - 2013/6/1

N2 - OBJECTIVES:We examined the effects of the black box warning about the risk of tardive dyskinesia (TD) with chronic use of metoclopramide on management of gastroparesis within a single clinical practice, and on reporting of adverse events.METHODS:Medical records of gastroparesis patients were evaluated for physician management choices. The FDA Adverse Event Reporting System (FAERS) was analyzed for event reports, and for lawyer-initiated reports, with metoclopramide from 2004 to 2010. Google Scholar was searched for court opinions against metoclopramide manufacturers.RESULTS:Before the black box warning, 69.8% of patients received metoclopramide for gastroparesis, compared with 23.7% after the warning. Gastroenterologists prescribed domperidone more often after than before the warning. Metoclopramide prescriptions decreased after 2008. Adverse event reporting increased after the warning. Only 3.6% of all FAERS reports but 70% of TD reports were filed by lawyers, suggesting a distortion in signal. Forty-seven legal opinions were identified, 33 from 2009-2010. CONCLUSIONS:The black box warning for metoclopramide has decreased its usage and increased its rate of adverse event reporting. Lawyer-initiated reports of TD hinder pharmacovigilance.

AB - OBJECTIVES:We examined the effects of the black box warning about the risk of tardive dyskinesia (TD) with chronic use of metoclopramide on management of gastroparesis within a single clinical practice, and on reporting of adverse events.METHODS:Medical records of gastroparesis patients were evaluated for physician management choices. The FDA Adverse Event Reporting System (FAERS) was analyzed for event reports, and for lawyer-initiated reports, with metoclopramide from 2004 to 2010. Google Scholar was searched for court opinions against metoclopramide manufacturers.RESULTS:Before the black box warning, 69.8% of patients received metoclopramide for gastroparesis, compared with 23.7% after the warning. Gastroenterologists prescribed domperidone more often after than before the warning. Metoclopramide prescriptions decreased after 2008. Adverse event reporting increased after the warning. Only 3.6% of all FAERS reports but 70% of TD reports were filed by lawyers, suggesting a distortion in signal. Forty-seven legal opinions were identified, 33 from 2009-2010. CONCLUSIONS:The black box warning for metoclopramide has decreased its usage and increased its rate of adverse event reporting. Lawyer-initiated reports of TD hinder pharmacovigilance.

UR - http://www.scopus.com/inward/record.url?scp=84878931697&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878931697&partnerID=8YFLogxK

U2 - 10.1038/ajg.2012.300

DO - 10.1038/ajg.2012.300

M3 - Article

C2 - 23735907

AN - SCOPUS:84878931697

VL - 108

SP - 866

EP - 872

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 6

ER -